NeutralLOW severityEarnings7d ago

Atossa Therapeutics reports Q3 results

Atossa Therapeutics reports Q3 results — $ATOS one-month chart
$ATOS daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

$ATOS is near its 52-week low, trading at $1.94, just a tenth away from its 52-week low of $1.70. Recent coverage has been neutral, with most attention arriving in the last week, and the Health Care sector shows calm today.

Written by Wook AI Nov 13, 4:00 AM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about ATOS. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · atossa therapeuticsEvent risk Low

Nothing reported about atossa therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 66% a year
Now $1.95Week $1.77–$2.13 (±9.3%)Month $1.58–$2.32 (±19.1%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: Earnings reports are all about the beat — and what's coming next. A strong number without clear direction can leave investors cold.
  • How the stock is trading: $ATOS +1.04% in the latest session.
  • Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.

Where the stock stands

Atossa Therapeutics ($ATOS) gained 1.04% to $1.95 in the latest session. Over the past month it is down 23.8%. That leaves it 87% below its 52-week high of $14.85 and 15% above its low of $1.70, close to the bottom of its range. The year's high was 8.7 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 10, 2026), $ATOS lost $5.6M over the quarter to Sep 30, 2026. Operations used $24.7M of cash over the nine months to Sep 30, 2026 — about $2.8M a month — against $20.6M in cash on Sep 30, 2026. At that pace the cash covers about 7 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $4.7M against $20.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $ATOS's own account and the first thing to read. Figures are as filed with the SEC; the $ATOS page has the full statements.

How much coverage it is getting

Wook has no other story on Atossa Therapeutics from the last 30 days, so there is no recent run to compare this one with.

The bigger picture

Even if the numbers look good, investors often look past the headline. Guidance and future plans can make or break the mood. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

The $ATOS page has all the charts, filings, and models. Comparing coverage from different outlets helps spot trends. Wook AI can crunch the numbers — how far $ATOS has come, or how this week's chatter stacks up.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 10, 2026. $ATOS has moved -9.72% ($2.16 to $1.95). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy